Lakeshore Biopharma Faces Imminent Nasdaq Delisting; Company Evaluates Options Ahead of Appeal Deadline
I'm PortAI, I can summarize articles.
LakeShore Biopharma Co., Ltd (Nasdaq: LSB) faces imminent delisting from Nasdaq due to its stock price falling below the required minimum bid price of $1.00 for 30 consecutive business days. Trading will be suspended on September 22, 2025, unless the company appeals by September 18, 2025. The company is currently evaluating options, including a potential appeal hearing.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments